Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
July 11, 2022 20:40 ET
|
Mesoblast Limited
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L,...
Mesoblast Key Opinion Leader Event Series for Investors & Analysts
June 09, 2022 07:00 ET
|
Mesoblast Limited
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the...
Operational Highlights and Financial Results for the Period Ended March 31, 2022
May 31, 2022 20:15 ET
|
Mesoblast Limited
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
Appendix 4C Quarterly Activity Report
April 28, 2022 20:35 ET
|
Mesoblast Limited
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
March 23, 2022 20:40 ET
|
Mesoblast Limited
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip R....
Operational Highlights and Financial Results for the Period Ended December 31, 2021
February 24, 2022 17:30 ET
|
Mesoblast Limited
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
Mesoblast Corporate Update and Financial Results Webcast
February 24, 2022 05:57 ET
|
Mesoblast Limited
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn’s Colitis After Direct Injection of Remestemcel-L by Colonoscopy
February 20, 2022 18:19 ET
|
Mesoblast Limited
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from...
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
February 01, 2022 19:20 ET
|
Mesoblast Limited
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment...
Appendix 4C Quarterly Activity Report
January 30, 2022 19:16 ET
|
Mesoblast Limited
NEW YORK, Jan. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational and...